Interventional Glaucoma

Robert L. Stamper, MD, discusses the current state of OCT angiography, and what remains on the horizon for glaucoma care.

Yvonne Ou, MD, discusses Glaucoma 360's first-ever "Shark Tank" competition at the 2019 meeting.

Drs. Graves and Iwach, co-founders of the Glaucoma 360 meeting, discuss the biggest advances in innovation and research at the 23rd annual meeting at the Palace Hotel in San Francisco on Feb. 2, 2019.

Shan C. Lin, MD, provides the key takeaways from his presentation at the annual Glaucoma 360 meeting.

L. Jay Katz, MD, delivered the Shaffer‐Hetherington‐Hoskins Lecture, "Screening for Glaucoma: New Strategies" at the 23rd annual Glaucoma 360 meeting at the Palace Hotel in San Francisco on Feb. 2, 2019. Here, he shares his take-home message for clinicians.

Researchers continue to explore device’s measurement of patterns, any correlation to IOP

Approach more cost-effective, considered as option for first-line therapy, suggests surgeon

How affordable are glaucoma interventions in developed and developing countries? Doug Katsev, MD, takes a look.

Steps to drive costs down include patient education, greater competition in marketplace

Latanoprostene bunod especially useful to patients who do not respond to first-line therapy

Novel platforms address adherence; clinicians look to efficacy, treatment duration

Here is one question to help clinicians decide: ‘What is the anatomy giving me?’

Exploring broad utility of netarsudil for ROCK inhibition across spectrum of glaucoma

Research to understand underlying mechanisms may lead to clues for targeted therapy